Log In
Print
BCIQ
Print
Print this Print this
 

sifalimumab (MEDI-545) (formerly MDX-1103)

  Manage Alerts
Collapse Summary General Information
Company Bristol-Myers Squibb Co.
DescriptionHuman mAb targeting interferon (IFN) alpha
Molecular Target Interferon (IFN) alpha
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase II
Standard IndicationLupus
Indication DetailsTreat systemic lupus erythematosus (SLE)
Regulatory Designation
Partner AstraZeneca plc

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$2,400.0M

$2,400.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today